楊沛然

教育及工作經(jīng)歷

2008-2017              英國劍橋大學(xué) (University of Cambridge) 學(xué)士、碩士、博士學(xué)位

2017-2020              美國哈佛大學(xué)醫學(xué)院 (Harvard Medical School) 博士后

2021-                       中國醫學(xué)科學(xué)院基礎醫學(xué)研究所&北京協(xié)和醫學(xué)院基礎學(xué)院“引進(jìn)人才”

現任生理學(xué)系課題組長(cháng)、博士研究生導師，加入院校準-長(cháng)聘教職系列。

研究領(lǐng)域與方向

肺血管病和呼吸系統疾病研究

從分子、細胞和整體動(dòng)物水平，結合多組學(xué)與臨床數據，研究肺動(dòng)脈高壓、塵肺病及慢阻肺等呼吸系統疾病發(fā)生發(fā)展中的病理生理學(xué)改變及重要分子機制；探索相關(guān)疾病的干預策略，尋找新靶點(diǎn)并進(jìn)行臨床前與轉化實(shí)驗。

課題組長(cháng)期與國內相關(guān)領(lǐng)域頂尖研究團隊、臨床醫院以及哈佛醫學(xué)院、劍橋大學(xué)團隊交流合作。

課題組招聘（2021-2022）

課題組計劃招聘1-2名助理研究員，需熟練掌握分子生物與生物化學(xué)實(shí)驗技術(shù)，能夠在課題組長(cháng)指導下開(kāi)展課題研究與基金申請工作，協(xié)助課題組長(cháng)指導研究生。

課題組長(cháng)期招收博士研究生／碩士研究生，歡迎對本課題組研究方向感興趣的同學(xué)報考。

聯(lián)系方式：

peiranyang@ibms.pumc.edu.cn

北京市東城區東單三條5號可勝大樓

代表性論文：

1. 1.Yang P, Bocobo GA, Yu PB. Sotatercept for Pulmonary Arterial Hypertension. (Letter to Editor) N Engl J Med 2021 385(1):92-93. PMID: 34192439.
2. 2.Yang P, Troncone L, Augur ZM, Kim SSJ, McNeil ME, Yu PB. The role of bone morphogenetic protein signaling in vascular calcification. (Review) Bone. 2020 141:115542. PMID: 32736145.
3. 3.Yung LM#, Yang P#, Joshi S, Augur ZM, Kim SSJ, Bocobo GA, Dinter T, Troncone L, Chen PS, McNeil ME, Southwood M, Poli de Frias S, Knopf J, Rosas IO, Sako D, Pearsall RS, Quisel JD, Li G, Kumar R, Yu PB. ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension. Sci Transl Med. 2020 12(543):eaaz5660. PMID: 32404506.
4. 4.Yang P#, Read C#, Kuc RE, Nyimanu D, Williams TL, Crosby A, Buonincontri G, Southwood M, Sawiak SJ, Morrell NW, Davenport AP, Maguire JJ. A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. Br J Pharmacol. 2019 176(9):1206-1221. PMID: 30710493.
5. 5.Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ*, Davenport AP*. Elabela/Toddler Is an endogenous agonist of the apelin APJ receptor in the adult cardiovascular system, and exogenous administration of the peptide compensates for the downregulation of its expression in pulmonary arterial hypertension. Circulation. 2017 135(12):1160-1173. PMID:28137936.
6. 6.Yang P, Kuc RE, Brame AL, Dyson A , Singer M, Glen RC, Cheriyan J, Wilkinson IB, Davenport AP, Maguire JJ. [Pyr1]Apelin(1-12) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr1]Apelin-13. Front Neurosci. 2017 11:92. PMID:28293165.
7. 7.Read C#, Fitzpatrick CM#, Yang P#, Kuc RE, Maguire JJ*, Glen RC*, Foster RE*, Davenport AP*. Cardiac action of the first G protein biased small molecule apelin agonist. Biochem Pharmacol. 2016 116:63-72. PMID:27475715.
8. 8.Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. (Review) Trends Pharmacol Sci. 2015 36(9):560-567. PMID: 26143239.